CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.The analysis — which included patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after endocrine therapy — also showed considerably
Related Keywords
United States ,Chicago ,Illinois ,Milan ,Lombardia ,Italy ,Giuseppe Curigliano ,Mindy Valcarcel ,Daiichi Sankyo ,Bymark Leiser ,Astrazeneca ,University Of Milan ,European Institute Of Oncology ,European Institute ,
comparemela.com © 2020. All Rights Reserved.